Oragenics OGEN 深 沪
已收盘 10-16 16:00:00 美东时间
0.4349
-0.001
-0.25%
华盛通- 最 高0.4538
- 今 开0.4538
- 成交量 3.27万股
- 最 低 0.43
- 昨 收 0.436
- 总市值 196.23万
- 52周最高 1.34
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 0.43
- 委 比 0.00%
- 总股本 451.20万
- 历史最高 83700.00
- 量 比 1.81
- 振 幅 5.46%
- 历史最低 0.43
- 每 手 1
- 风险率 0.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oragenics Faces NYSE Compliance Challenges Amid Trial Progress
Oragenics ( ($OGEN) ) just unveiled an update. On August 26, 2026, Oragenics, I...
08-29 05:36
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
Oragenics, Inc. provided updates on its Phase IIa clinical trial for mTBI, U.S. regulatory pathway, and NYSE American listing status. The company has dosed nine participants across three active clinical sites in Australia. It received FDA feedback on its Type B meeting request and plans to submit an IND application by year-end. Oragenics received a deficiency letter from NYSE American due to non-compliance with continued listing standards, requir...
08-28 20:25
Oragenics Highlights Investor Outreach at Micro-Cap Conference
The latest update is out from Oragenics ( ($OGEN) ). On May 18, 2026, Oragenics...
05-19 20:58
Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY
Oragenics (AMEX:OGEN) reported quarterly losses of $(0.51) per share. This is a 85.83 percent increase over losses of $(3.60) per share from the same period last year.
05-09 06:14
Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain BarrierSarasota, FL and San Diego, CA, May 07,
05-07 20:34
Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stagesSARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage
04-20 21:04
Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need
04-13 20:34
Oragenics Sets New 2025 Annual Shareholder Meeting Date
The latest update is out from Oragenics ( ($OGEN) ). On March 27, 2026, Orageni...
04-01 07:45
